Sophiris Bio Inc (SPHS) Trading Down 5.9%
Shares of Sophiris Bio Inc (NASDAQ:SPHS) fell 5.9% on Wednesday . The company traded as low as $4.66 and last traded at $5.31, with a volume of 10,050,182 shares changing hands. The stock had previously closed at $5.64.
A number of brokerages have weighed in on SPHS. Echelon Wealth Partners reissued a “buy” rating and issued a $5.00 price target on shares of Sophiris Bio in a report on Friday, June 10th. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of Sophiris Bio in a report on Friday, June 10th.
The firm’s 50 day moving average price is $2.64 and its 200 day moving average price is $1.80. The company’s market capitalization is $106.37 million.
Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.06. On average, analysts predict that Sophiris Bio Inc will post ($0.73) earnings per share for the current year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.